Company Chairman introduces new, non-invasive congestive heart failure monitoring device to be deployed in hospitals, physicians’ offices, and home markets, pending regulatory approval, by end of year.
Vixiar Medical, Inc. announced today that Robert Storey, Maryland Managing Director of VIC Technology Venture Development™ and the Chairman of Vixiar Medical, was a presenter at the Coulter Foundation Investor Forum held at Stanford University’s Francis C. Arrillaga Alumni Center in Palo Alto, California.
The Wallace H. Coulter Foundation funds translational research in biomedical engineering through endowment and grants to sixteen of the nation’s top biomedical engineering schools. The program funds joint research between biomedical engineering investigators and clinicians, and supports the most promising technologies that can progress towards commercial development and enter the clinical practice. The top 25 start-up companies spun out of this process were invited to present at the investor forum.
The Vixiar product, based on technology licensed from Johns Hopkins University, allows rapid and repetitive assessment of cardiac filling pressures – a critical measurement in the management of heart failure hospital readmissions. The inexpensive wireless device can be used at the point of care by a physician/nurse, or the patient can utilize a self-directed set of procedures to conduct the tests remotely and non-invasively over several minutes. The normal process for obtaining cardiac filling pressures requires an invasive catheterization procedure at a lab, in which a pressure catheter is run through the patient’s artery into the heart chambers for direct measurement.
Vixiar prototypes have been tested on several hundred patients to date, and are currently being used in four separate clinical trials. Vixiar expects its heart monitor to be deployed in hospitals, physicians’ offices, and home markets with an initial release, pending regulatory approval, by the end of 2015.
Congestive Heart Failure is being treated in approximately 6 million people in the US and about 25 million worldwide. It accounts for 1.2 million hospital admissions in the US each year and is the number one cause of hospital readmissions within 30 days of discharge. Hospital treatment costs are about $40 billion per year, and nearly 10% of those expenditures are unreimbursed due to readmissions that occur within 30 days. Improved monitoring of increasing cardiac filling pressures is considered the important criteria to allow intervention before a patient progresses to hospitalization.
About Vixiar Medical™
Vixiar Medical, Inc, is involved in the development of innovative technologies for the treatment and monitoring of cardiopulmonary disease. Headquartered in Annapolis, Maryland, it is part of the VIC Technology group of companies. Contact Robert Storey, Chairman of Vixiar, and Maryland Managing Director of VIC Technology Venture Development, at email@example.com or (443) 603-0212. http://www.vixiar.com
About VIC Technology Venture Development™
VIC Technology is a for-profit firm involved in the licensing and formation of companies that are based on technologies from university and federal labs. The group currently has 14 companies in its active portfolio and maintains offices in Annapolis, Boston, and Fayetteville, Arkansas. http://www.victvd.com